SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Community sentiment remains heavily polarized as traders weigh the potential market impact of proposed economic sanctions against Iran and ongoing trade friction with Canada. Discussion is dominated by heated political debates and speculation regarding pending mergers and corporate catalysts that could influence the stock's future direction.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors debate the potential for a long-term recovery, fueled by persistent community discussions regarding its utility in payment infrastructure and the ongoing impact of regulatory milestones like the CLARITY Act. While some community members remain optimistic about stacking during current price levels, others express frustration over historical performance and leadership changes, highlighting a deep divide in sentiment.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing significant volatility as retail investors weigh delayed launch updates and broader sector pressure against the company's strong commercial partnerships, including a potential high-stakes interest in 800 MHz spectrum. While the community remains divided over management's communication and the pace of satellite deployment, many shareholders are viewing the current price consolidation as a long-term buying opportunity.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending amid a broad rally in crypto-related equities as traders react to a White House meeting with industry leaders aimed at advancing the Clarity Act. Community sentiment remains highly active as investors debate whether this momentum signals a sustained bull cycle or another opportunity for profit-taking in a historically volatile stock.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

UAMY is trending as investors react to a significant revenue miss and a lowered annual guidance, driven by a sharp decline in antimony prices. Community discussion remains polarized between frustrated investors concerned about management's execution and those viewing the dip as a long-term accumulation opportunity for a critical domestic mineral producer.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors weigh its upcoming earnings against broader semiconductor sector volatility, with community sentiment divided between expectations of a blowout performance and skepticism fueled by circular financing concerns. Traders are actively debating whether current price action represents a strategic shakeout before a post-earnings rally or a deeper correction linked to macro-economic uncertainty.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is attracting significant institutional attention as investors monitor its expanding oncology pipeline and ongoing M&A activity following a series of strategic acquisitions, including Assembly Biosciences and Arcellx. Community discourse remains heavily focused on the company's HIV franchise strength and potential long-term value as the stock maintains a technical base near key support levels.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending due to the company establishing a new $1.59 billion USD cash pool, sparking significant community debate over its ongoing share dilution versus its strategy to increase liquidity. Investors are actively discussing the stock's role as a proxy for Bitcoin, with sentiment split between bullish expectations for a squeeze and skepticism regarding the sustainability of the company's financing model.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is facing intense market pressure following an FDA clinical hold on its experimental Hunter syndrome gene therapy, RGX-121, after asymptomatic spinal abnormalities were discovered in trial participants. While the company stated that investigators and radiologists consider these findings benign and reported no neurocognitive decline, investors are expressing frustration over the lack of a near-term path forward and are debating whether the stock's current price is an extreme overreaction to the regulatory setback.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is seeing increased investor scrutiny and community activity as shareholders weigh heavy insider accumulation against recent technical volatility and earnings guidance adjustments. The stock is a frequent subject of bottom-fishing debates, with the community closely tracking institutional sentiment and potential turnaround catalysts in its medical device pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$COLL   Got Opium ?  re-entry 12:11 pm edt 8/20 bigger position this time around.  
 
08/20/2026  
Buy 
 
COLL COLLEGIUM PHARMACEUTICAL 350 $27.74  -$9,709.00 More 
08/18/2026  
Sell 
 
COLL COLLEGIUM PHARMACEUTICAL 30 $28.34 $0.03 $850.17 More 
08/17/2026  
Buy 
 
COLL COLLEGIUM PHARMACEUTICAL 30 $28.25  -$847.50 More 
08/17/2026  
Sell 
 
COLL COLLEGIUM PHARMACEUTICAL 201 $28.85 $0.16 $5,798.69 More 
08/14/2026  
Buy 
 
COLL COLLEGIUM PHARMACEUTICAL 201 $27.98  -$5,623.98 More 
08/13/2026  
Sell 
 
COLL COLLEGIUM PHARMACEUTICAL 200 $28.32 $0.16 $5,663.84

StockTwits Web

Collegium Pharmaceutical Inc

   Got Opium ?  re-entry 12:11 pm edt 8/20 bigger position this time around.  
 
08/20/2026  
Buy 
 
COLL COLLEGIUM PHARMACEUTICAL 350 $27.74  -$9,709.00 More 
08/18/2026  
Sell 
 
COLL COLLEGIUM PHARMACEUTICAL 30 $28.34 $0.03 $850.17 More 
08/17/2026  
Buy 
 
COLL COLLEGIUM PHARMACEUTICAL 30 $28.25  -$847.50 More 
08/17/2026  
Sell 
 
COLL COLLEGIUM PHARMACEUTICAL 201 $28.85 $0.16 $5,798.69 More 
08/14/2026  
Buy 
 
COLL COLLEGIUM PHARMACEUTICAL 201 $27.98  -$5,623.98 More 
08/13/2026  
Sell 
 
COLL COLLEGIUM PHARMACEUTICAL 200 $28.32 $0.16 $5,663.84